Archive for the ‘Pharmaceutical Drug Injuries’ Category
Posted by Mark Blane on August 11th, 2009 under Class Action Lawsuits, Defective Products, Pharmaceutical Drug Injuries Tags: aprotinin, excessive bleeding, heart surgery, Trasylol lawsuits •
No Comments
There are estimates that at least 10,000 patients may unnecessarily have suffered kidney damage due to use of aprotinin (Trasylol) during heart surgery. Many patients may have been injected with Trasylol to reduce blood loss during coronary artery bypass (CABG) surgery. Thus, the goal with using Trasylol was to stop bleeding during the heart bypass [...]
Posted by Mark Blane on August 11th, 2009 under Class Action Lawsuits, Defective Products, Pharmaceutical Drug Injuries Tags: anti-epilepsy medication, Neurontin lawsuits, Pfizer, suicide risk •
No Comments
In a move that was unexpected, the first Neurontin trial has ended with a dismissal, after an anonymous donor offered to put money in a trust fund for the 10-year-old daughter of a Massachusetts woman who committed suicide two years after taking the anti-seizure drug. Plaintiff’s lawyer Mark Lanier told Bloomberg Television that the anonymous donor was [...]
Posted by Mark Blane on August 11th, 2009 under Class Action Lawsuits, Defective Products, Pharmaceutical Drug Injuries Tags: Alendronate Sodium, Dead Jaw, Fosamax lawsuits, jaw bone, Jaw Death, ONJ •
2 Comments
Fosamax® (Alendronate Sodium) is a member of a class of drugs known as “bisphosphonates.” Manufactured by Merck & Co., Fosamax was approved by the U.S. Food and Drug Administration in 1995, and is commonly used to treat patients with osteoporosis and Paget’s disease. Fosamax and other bisphosphonates, including Aredia® and Zometa®, have been linked to [...]
Posted by Mark Blane on August 11th, 2009 under Class Action Lawsuits, Defective Products, Pharmaceutical Drug Injuries Tags: claimants, claims administators, Merck, points award, Vioxx settlement update •
4 Comments
Merck, the manufacturer of Vioxx, has begun to make partial payments to some qualified Vioxx claimants who had heart attacks as direct result of taking their once famed drug. Of the more than 50,000 potential claims, only a few hundred were paid in August, and most other pending claims will actually be paid at a [...]
Posted by Mark Blane on August 8th, 2009 under Class Action Lawsuits, Defective Products, Pharmaceutical Drug Injuries Tags: Merck, Schering-Plough, settlement, Vytorin, Zetia •
No Comments
According to Reuters out of New York, Merck & Co, and Schering-Plough Corp will pay $41.5 million to settle class-action lawsuits over their shared cholesterol drugs Vytorin, and Zetia, the companies said on Wednesday, August 5, 2009.
The lawsuits involved allegations arising from the Enhance clinical trial, whose results released in January 2008, raised serious questions about [...]
Posted by Mark Blane on August 1st, 2009 under Class Action Lawsuits, Defective Products, Pharmaceutical Drug Injuries Tags: Avandia, bone fractures, diabetes, liver problems, Rosiglitazone •
No Comments
The pharmaceutical drug Avandia, also known as Rosiglitazone, is a drug that is taken for the treatment of diabetes. Recent medical studies have shown its use increases the risk of a heart attack (myocardial infarction) by approximately 30% – 40%. It has also been shown to increase other health risks such as: Congestive Heart Failure; [...]
Posted by Mark Blane on July 28th, 2009 under Class Action Lawsuits, Defective Products, Pharmaceutical Drug Injuries Tags: heart attacks, investors, Merck, Vioxx Derivative Law Suit •
No Comments
It is now going on almost five years since the drug Vioxx was pulled from store shelves by its manufacturer, Merck, but it appears the legal system will be seeing the class action against Merck for sometime to come.
On May 26, 2009, the Supreme Court agreed to hear Merck’s appeal in a shareholder lawsuit that [...]
Posted by Mark Blane on July 28th, 2009 under Class Action Lawsuits, Defective Products, Pharmaceutical Drug Injuries Tags: Anosmia, matrixx, Zicam, zicam cold remedy •
No Comments
Lawyers representing approximately 117 people who claim to have suffered loss of smell after using the popular nasal spray have filed lawsuit against the Scottsdale, Arizona based drug manufacturer Matrixx on June 22, 2009. Several of the plaintiffs live in the Phoenix, Arizona area, and one, a owner of a well known, and upscale, Las [...]
Posted by Mark Blane on July 8th, 2009 under Class Action Lawsuits, Defective Products, Pharmaceutical Drug Injuries Tags: Attorney Mark C. Blane, Hydroxycut, Hydroxycut 24, Hydroxycut Max •
No Comments
Reports of liver damage and other injuries were reported after a recall was made on Hydroxycut products; a Pharmaceutical Class Action lawsuit has been filed in Canada of all places alleging the manufacturer of Hydroxycut products misled the public about the true safety of the weight-loss aid.
The product Hydroxycut is manufactured by Lovate Health Sciences [...]
Posted by Mark Blane on July 7th, 2009 under Class Action Lawsuits, Defective Products, Pharmaceutical Drug Injuries Tags: Duragesic, Fentanyl, leak, pain patches •
No Comments
The recall of the Duragesic Pain Patches was done by Johnson & Johnson, and Novartis after the discovery of manufacturer defects that may cause the pain patches to leak a toxic fluid. The toxic fluid was identified as Fentanyl, and the leak could lead to fatal overdoeses. All of the Duragestic patches that are set [...]